Mr. Kevin GUNAWANIndonesia
Division of Neurosurgery, Department of Surgery, National Taiwan University Hospital; Department of Neurosurgery, Cipto Mangunkusumo National General Hospital
| 2024-now to present | Trainee at National Taiwan University Hospital |
| 2019-now to present | Attending Neurosurgeon, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia |
| 2024 - now | Trainee at National Taiwan University Hospital |
| 2021 - 2023 | Epilepsy surgery fellowship, Semarang Epilepsy Center, Semarang, Indonesia |
| 2014 - 2019 | Neurosurgery Training, Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia |
Epilepsy surgery, movement disorder surgery, pediatric Neurosurgery
As a medical professional, my utmost desire is to provide the best healthcare service for my patients. I’m passionate about pediatric neurosurgery, epilepsy, and functional stereotactic neurosurgery. I love to work as a team, treat patients with love, compassion, and genuineness.
Indirect revascularization for hemorrhagic moyamoya disease
1109 15:50-16:00
Interim Meeting of AASPN/303A
Moyamoya disease (MMD) is an idiopathic cerebrovascular disease characterized by progressive narrowing of the bilateral terminal portion of the internal carotid artery (ICA), followed by development of collateral vascular network formation at the base of the brain.(1) Brain ischemia and hemorrhage are the most common manifestations of MMD, and the term of hemorrhagic moyamoya disease (HMMD) referred to hemorrhagic events associated with MMD.(2–4) Those events could manifest ranging from transient ischemic attack (TIA), to persistent neurological deficits such as motor impairment, speech, sensory disturbances, syncope, headache, movement disorder, and seizure.(2,5)
Currently, revascularization surgery is the standard treatment for MMD, as it has been proven more effective than conservative approaches in improving cerebral perfusion and preventing recurrent strokes. However, the effectiveness and outcomes of revascularization surgery in HMMD remain a subject of debate. Although intracranial hemorrhage is less common than ischemic events, it is the major cause of death in patients with MMD, with mortality rate after rebleeding is as high as 44.7%.(2,4) Key among the goals of treating hemorrhagic MMD is to reduce the risk of future intracranial hemorrhages.
The available research on the efficacy and safety of revascularization surgery, particularly indirect revascularization in HMMD, is limited. We share and evaluate the outcomes of indirect revascularization in HMMD.